<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404651</url>
  </required_header>
  <id_info>
    <org_study_id>A3L11</org_study_id>
    <nct_id>NCT00404651</nct_id>
  </id_info>
  <brief_title>Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants</brief_title>
  <official_title>Lot to Lot Consistency Study of DTaP-IPV-Hep B-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Mexican Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to clinically confirm that the manufacturing process of the
      final bulk products of the investigational DTaP-IPV-HB-PRP~T vaccine is consistent.

      The primary objective is to demonstrate the equivalence of three batches of DTaP-IPV-HB-PRP~T
      vaccine, in terms of seroprotection and seroconversion rates for the vaccine antigens after
      the three-dose primary series.

      The secondary objectives are:

        -  To describe in each group, the immunogenicity parameters for all antigens one month
           after the third dose of the primary series

        -  To assess the overall safety in each group one month after the third dose of the primary
           series.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine</measure>
    <time_frame>Day 150 (one month post-dose 3)</time_frame>
    <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for Diphtheria (D) by toxin neutralization test, and for Tetanus (T) by enzyme-linked immunosorbent assay (ELISA). Seroprotection was defined as a titer ≥ 0.10 mIU/mL for Hep B, ≥ 0.15 µg/mL for PRP, and ≥ 0.01 IU/mL for D and T antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Equivalence of Seroprotection Against Pertussis in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine.</measure>
    <time_frame>Day 150 (one month post-dose 3)</time_frame>
    <description>Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as a ≥ 4 fold increase in titer from Day 0 (before dose 1) to Day 150, one month post-dose 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Equivalence of Seroprotection Against Poliovirus Types 1, 2, and 3 in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine</measure>
    <time_frame>Day 150 (one month post-dose 3)</time_frame>
    <description>Antibody titers were measured for poliovirus types 1, 2, and 3 by Enzyme immuno assay. Seroprotection against Poliovirus Types 1, 2, and 3 was defined as a titer ≥ 8 (1/dilutions).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Antibodies After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine</measure>
    <time_frame>Day 150 (one month post-dose 3)</time_frame>
    <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for diphtheria (D) by toxin neutralization test, and for tetanus by enzyme linked immunosorbent assay. Antibody titers were measured for poliovirus types 1, 2, and 3 by neutralization assay. Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine</measure>
    <time_frame>Day 0 (pre-each vaccination) up to 7 days post-each dose</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Fever ([pyrexia] - temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1189</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Hepatitis B</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive vaccine Batch A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive vaccine Batch B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive vaccine Batch C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Infanrix hexa™</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-HB-PRP~T vaccine</intervention_name>
    <description>0.5 mL, intramuscular (IM)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-HB-PRP~T vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-HB-PRP~T vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-HBV-IPV vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>INFANRIX®HEXA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Two months old infants on the day of inclusion

          -  Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg

          -  Informed consent form signed by one or both parents or by the guardian and two
             independent witnesses

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  Received Bacillus Calmette Guerin (BCG) vaccine between birth and one month of life in
             agreement with the national immunization calendar.

        Exclusion Criteria :

          -  Participation in another clinical trial in the four weeks preceding the (first) trial
             vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Congenital or acquired immunodeficiency

          -  Systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or a vaccine containing the same
             substances

          -  Chronic illness at a stage that could interfere with trial conduct or completion

          -  Blood or blood-derived products received since birth

          -  Any vaccination in the four weeks preceding the first trial visit

          -  Any planned vaccination (except BCG, rotavirus, and pneumococcal conjugated vaccines)
             during the study

          -  Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus
             influenzae type b or hepatitis B infection(s) (confirmed either clinically,
             serologically or microbiologically)

          -  Previous vaccination against hepatitis B, pertussis, tetanus, diphtheria, poliovirus,
             or Haemophilus influenzae type b infection(s)

          -  Known personal or maternal history of HIV, Hepatitis B (HBsAg) or Hepatitis C
             seropositivity

          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

          -  History of seizures

          -  Febrile (rectal equivalent temperature ≥ 38.0°C) or acute illness on the day of
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Estado de Mexico</city>
        <zip>56613</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Estado de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Insurgentes Cuicuilco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tlalpan</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <results_first_submitted>February 14, 2014</results_first_submitted>
  <results_first_submitted_qc>April 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2014</results_first_posted>
  <last_update_submitted>April 11, 2014</last_update_submitted>
  <last_update_submitted_qc>April 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Invasive Haemophilus influenzae type b.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 14 November 2006 to 13 July 2007 in 6 clinical centers in Mexico.</recruitment_details>
      <pre_assignment_details>A total of 1189 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DTaP-IPV-HB-PRP~T Batch 1</title>
          <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P2">
          <title>DTaP-IPV-HB-PRP~T Batch 2</title>
          <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P3">
          <title>DTaP-IPV-HB-PRP~T Batch 3</title>
          <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Infanrix Hexa™</title>
          <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="343"/>
                <participants group_id="P3" count="339"/>
                <participants group_id="P4" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="315"/>
                <participants group_id="P3" count="294"/>
                <participants group_id="P4" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTaP-IPV-HB-PRP~T Batch 1</title>
          <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B2">
          <title>DTaP-IPV-HB-PRP~T Batch 2</title>
          <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B3">
          <title>DTaP-IPV-HB-PRP~T Batch 3</title>
          <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Infanrix Hexa™</title>
          <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="340"/>
            <count group_id="B2" value="343"/>
            <count group_id="B3" value="339"/>
            <count group_id="B4" value="167"/>
            <count group_id="B5" value="1189"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="339"/>
                    <measurement group_id="B4" value="167"/>
                    <measurement group_id="B5" value="1189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.00" spread="0.200"/>
                    <measurement group_id="B2" value="2.00" spread="0.197"/>
                    <measurement group_id="B3" value="2.01" spread="0.193"/>
                    <measurement group_id="B4" value="1.98" spread="0.189"/>
                    <measurement group_id="B5" value="2.00" spread="0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="339"/>
                    <measurement group_id="B4" value="167"/>
                    <measurement group_id="B5" value="1189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine</title>
        <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for Diphtheria (D) by toxin neutralization test, and for Tetanus (T) by enzyme-linked immunosorbent assay (ELISA). Seroprotection was defined as a titer ≥ 0.10 mIU/mL for Hep B, ≥ 0.15 µg/mL for PRP, and ≥ 0.01 IU/mL for D and T antibodies.</description>
        <time_frame>Day 150 (one month post-dose 3)</time_frame>
        <population>Seroprotection was assessed in participants that received a vaccine who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population). Total number (N) are those with available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-HB-PRP~T Batch 1</title>
            <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-HB-PRP~T Batch 2</title>
            <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-HB-PRP~T Batch 3</title>
            <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine</title>
          <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for Diphtheria (D) by toxin neutralization test, and for Tetanus (T) by enzyme-linked immunosorbent assay (ELISA). Seroprotection was defined as a titer ≥ 0.10 mIU/mL for Hep B, ≥ 0.15 µg/mL for PRP, and ≥ 0.01 IU/mL for D and T antibodies.</description>
          <population>Seroprotection was assessed in participants that received a vaccine who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population). Total number (N) are those with available data for the endpoint.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hep B (N = 230, 234, 236, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="231" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="221" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="119" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP (N = 231, 236, 228, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="232" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="226" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="118" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria (N = 231, 236, 228, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="228" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="222" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="118" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus (N = 231, 236, 227, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="236" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="227" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="119" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Equivalence of Seroprotection Against Pertussis in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine.</title>
        <description>Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as a ≥ 4 fold increase in titer from Day 0 (before dose 1) to Day 150, one month post-dose 3.</description>
        <time_frame>Day 150 (one month post-dose 3)</time_frame>
        <population>Seroconversion was assessed in all participants who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-HB-PRP~T Batch 1</title>
            <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-HB-PRP~T Batch 2</title>
            <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-HB-PRP~T Batch 3</title>
            <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Equivalence of Seroprotection Against Pertussis in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine.</title>
          <description>Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as a ≥ 4 fold increase in titer from Day 0 (before dose 1) to Day 150, one month post-dose 3.</description>
          <population>Seroconversion was assessed in all participants who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Pertussis (N= 228, 234, 223, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="226" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="218" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="113" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N= 227, 233, 221, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="229" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="216" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="111" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Equivalence of Seroprotection Against Poliovirus Types 1, 2, and 3 in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine</title>
        <description>Antibody titers were measured for poliovirus types 1, 2, and 3 by Enzyme immuno assay. Seroprotection against Poliovirus Types 1, 2, and 3 was defined as a titer ≥ 8 (1/dilutions).</description>
        <time_frame>Day 150 (one month post-dose 3)</time_frame>
        <population>Seroprotection was assessed in all participants who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-HB-PRP~T Batch 1</title>
            <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-HB-PRP~T Batch 2</title>
            <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-HB-PRP~T Batch 3</title>
            <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Equivalence of Seroprotection Against Poliovirus Types 1, 2, and 3 in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine</title>
          <description>Antibody titers were measured for poliovirus types 1, 2, and 3 by Enzyme immuno assay. Seroprotection against Poliovirus Types 1, 2, and 3 was defined as a titer ≥ 8 (1/dilutions).</description>
          <population>Seroprotection was assessed in all participants who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1 (N = 231, 236, 225, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="236" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="225" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="119" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 (N = 230, 236, 226, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="236" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="226" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="118" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 (N = 230, 236, 226, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="235" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="226" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="117" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Antibodies After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine</title>
        <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for diphtheria (D) by toxin neutralization test, and for tetanus by enzyme linked immunosorbent assay. Antibody titers were measured for poliovirus types 1, 2, and 3 by neutralization assay. Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 150 (one month post-dose 3)</time_frame>
        <population>Geometric Mean Titers were assessed in all participants with endpoint data who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-HB-PRP~T Batch 1</title>
            <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-HB-PRP~T Batch 2</title>
            <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-HB-PRP~T Batch 3</title>
            <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine</title>
          <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for diphtheria (D) by toxin neutralization test, and for tetanus by enzyme linked immunosorbent assay. Antibody titers were measured for poliovirus types 1, 2, and 3 by neutralization assay. Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA).</description>
          <population>Geometric Mean Titers were assessed in all participants with endpoint data who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hep B (N = 230, 234, 226, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="935" lower_limit="755" upper_limit="1158"/>
                    <measurement group_id="O2" value="1566" lower_limit="1288" upper_limit="1905"/>
                    <measurement group_id="O3" value="1009" lower_limit="814" upper_limit="1252"/>
                    <measurement group_id="O4" value="1576" lower_limit="1283" upper_limit="1934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP (N = 231, 236, 228, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="9.77" upper_limit="14.5"/>
                    <measurement group_id="O2" value="13.1" lower_limit="10.7" upper_limit="16.0"/>
                    <measurement group_id="O3" value="11.5" lower_limit="9.26" upper_limit="14.3"/>
                    <measurement group_id="O4" value="6.68" lower_limit="5.10" upper_limit="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria (N = 231, 236, 228, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.176" lower_limit="0.143" upper_limit="0.217"/>
                    <measurement group_id="O2" value="0.246" lower_limit="0.194" upper_limit="0.311"/>
                    <measurement group_id="O3" value="0.173" lower_limit="0.139" upper_limit="0.214"/>
                    <measurement group_id="O4" value="0.173" lower_limit="0.132" upper_limit="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus (N = 231, 236, 227, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.67" upper_limit="2.15"/>
                    <measurement group_id="O2" value="1.86" lower_limit="1.64" upper_limit="2.10"/>
                    <measurement group_id="O3" value="1.77" lower_limit="1.57" upper_limit="2.01"/>
                    <measurement group_id="O4" value="2.20" lower_limit="1.93" upper_limit="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 (N = 231, 236, 225, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="860" lower_limit="725" upper_limit="1021"/>
                    <measurement group_id="O2" value="945" lower_limit="809" upper_limit="1102"/>
                    <measurement group_id="O3" value="843" lower_limit="712" upper_limit="999"/>
                    <measurement group_id="O4" value="1370" lower_limit="1082" upper_limit="1736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 (N = 230, 236, 226, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1689" lower_limit="1429" upper_limit="1996"/>
                    <measurement group_id="O2" value="1665" lower_limit="1416" upper_limit="1957"/>
                    <measurement group_id="O3" value="1612" lower_limit="1374" upper_limit="1892"/>
                    <measurement group_id="O4" value="2337" lower_limit="1878" upper_limit="2909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 (N = 230, 235, 226, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1198" lower_limit="1015" upper_limit="1413"/>
                    <measurement group_id="O2" value="1170" lower_limit="995" upper_limit="1377"/>
                    <measurement group_id="O3" value="962" lower_limit="809" upper_limit="1143"/>
                    <measurement group_id="O4" value="2186" lower_limit="1752" upper_limit="2727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertusiss toxoid (N = 230, 235, 226, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242" lower_limit="226" upper_limit="260"/>
                    <measurement group_id="O2" value="238" lower_limit="220" upper_limit="258"/>
                    <measurement group_id="O3" value="241" lower_limit="222" upper_limit="262"/>
                    <measurement group_id="O4" value="228" lower_limit="205" upper_limit="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N = 230, 234, 226, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243" lower_limit="228" upper_limit="259"/>
                    <measurement group_id="O2" value="256" lower_limit="237" upper_limit="277"/>
                    <measurement group_id="O3" value="220" lower_limit="202" upper_limit="239"/>
                    <measurement group_id="O4" value="182" lower_limit="165" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Fever ([pyrexia] - temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability</description>
        <time_frame>Day 0 (pre-each vaccination) up to 7 days post-each dose</time_frame>
        <population>Solicited reactions were assessed in all subjects who received at least one dose of vaccine, according to the vaccine actually received (Safety Analysis Population). Two batch 1 subjects got batch 2 vaccine, and 1 batch 1 got batch 3 vaccine. Total number (N) are those with available data for the outcome</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-HB-PRP~T Batch 1</title>
            <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-HB-PRP~T Batch 2</title>
            <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-HB-PRP~T Batch 3</title>
            <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Fever ([pyrexia] - temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability</description>
          <population>Solicited reactions were assessed in all subjects who received at least one dose of vaccine, according to the vaccine actually received (Safety Analysis Population). Two batch 1 subjects got batch 2 vaccine, and 1 batch 1 got batch 3 vaccine. Total number (N) are those with available data for the outcome</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="345"/>
                <count group_id="O3" value="340"/>
                <count group_id="O4" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Post-dose 1 (N = 323, 336, 329, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="237" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="225" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="95" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-dose 2 (N = 310, 319, 316, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="220" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="199" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="88" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Pos-dose 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="209" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="198" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="87" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema-Post dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="97" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="97" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="41" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 2 (N = 310, 319, 315, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="101" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="96" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="33" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="94" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="101" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="43" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="86" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="80" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="35" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-dose 2 (N = 310, 319, 315, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="70" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="60" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="26" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-dose 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="65" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="72" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="22" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia Post-dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="77" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="82" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="17" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia Post-dose 2 (N = 310, 318, 315, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="84" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="85" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="32" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia Post-dose 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="85" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="70" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="28" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Post-dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="63" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="56" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="27" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Post-dose 2 (N = 310, 319, 316, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="46" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="34" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="18" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Post-dose 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="46" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="47" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="20" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Post-dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="156" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="148" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="62" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Post-dose 2 (N=310, 319, 316, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="145" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="134" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="59" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Post-dose 3 (N=302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="118" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="122" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="40" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence Post-dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="110" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="102" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="45" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence Post-dse 2 (N = 310, 319, 316, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="78" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="65" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="24" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence Post-dose 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="57" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="54" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="20" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia Post-dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="70" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="27" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia Post-dose 2 (N = 310, 319, 315, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="64" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="65" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="25" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia Post-dose 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="58" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="65" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="29" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability Post-dose 1 (N = 323, 336, 329, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="198" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="193" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="83" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability Post-dose 2 (N = 310, 319, 316, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="192" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="174" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="72" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability Post-dse 3 (N = 302, 317, 306, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="167" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="165" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="69" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 after the first vaccination for up to 10 months (Day 300) post-vaccination.</time_frame>
      <desc>Safety was assessed in all participants who received at least one dose of vaccine, according to the vaccine actually received (Safety Analysis Population). Two participants randomized to Batch 1 got Batch 2 vaccine; 1 Batch 1 participant got Batch 3 vaccine. Total number (N) for each safety parameter are those with available data.</desc>
      <group_list>
        <group group_id="E1">
          <title>DTaP-IPV-HB-PRP~T Batch 1</title>
          <description>Participants received 3 doses of Batch 1 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="E2">
          <title>DTaP-IPV-HB-PRP~T Batch 2</title>
          <description>Participants received 3 doses of Batch 2 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="E3">
          <title>DTaP-IPV-HB-PRP~T Batch 3</title>
          <description>Participants received 3 doses of Batch 3 of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine, conjugated to tetanus protein (DTaP-IPV-HB-PRP~T), with one dose each at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="E4">
          <title>Infanrix Hexa™</title>
          <description>Participants received 3 doses of diphtheria (D), tetanus (T), pertussis (2 component acellular), recombinant hepatitis B Hansenula (Hep B) and poliomyelitis (IPV) vaccine adsorbed (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) vaccine conjugated to tetanus protein , with one dose each at 2, 4, and 6 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="340"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Disease Congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="340"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Food Intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Infantile Spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="237" subjects_at_risk="345"/>
                <counts group_id="E3" subjects_affected="225" subjects_at_risk="340"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="323"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="336"/>
                <counts group_id="E3" events="56" subjects_affected="56" subjects_at_risk="329"/>
                <counts group_id="E4" events="27" subjects_affected="27" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="220" subjects_affected="220" subjects_at_risk="323"/>
                <counts group_id="E2" events="237" subjects_affected="237" subjects_at_risk="336"/>
                <counts group_id="E3" events="225" subjects_affected="225" subjects_at_risk="329"/>
                <counts group_id="E4" events="95" subjects_affected="95" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="95" subjects_affected="95" subjects_at_risk="302"/>
                <counts group_id="E2" events="101" subjects_affected="101" subjects_at_risk="319"/>
                <counts group_id="E3" events="101" subjects_affected="101" subjects_at_risk="306"/>
                <counts group_id="E4" events="43" subjects_affected="43" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="74" subjects_affected="74" subjects_at_risk="310"/>
                <counts group_id="E2" events="86" subjects_affected="86" subjects_at_risk="336"/>
                <counts group_id="E3" events="80" subjects_affected="80" subjects_at_risk="329"/>
                <counts group_id="E4" events="35" subjects_affected="35" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="188" subjects_affected="188" subjects_at_risk="323"/>
                <counts group_id="E2" events="198" subjects_affected="198" subjects_at_risk="336"/>
                <counts group_id="E3" events="193" subjects_affected="193" subjects_at_risk="329"/>
                <counts group_id="E4" events="83" subjects_affected="83" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="75" subjects_affected="75" subjects_at_risk="310"/>
                <counts group_id="E2" events="85" subjects_affected="85" subjects_at_risk="317"/>
                <counts group_id="E3" events="85" subjects_affected="85" subjects_at_risk="315"/>
                <counts group_id="E4" events="32" subjects_affected="32" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="323"/>
                <counts group_id="E2" events="75" subjects_affected="75" subjects_at_risk="336"/>
                <counts group_id="E3" events="70" subjects_affected="70" subjects_at_risk="329"/>
                <counts group_id="E4" events="29" subjects_affected="29" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="93" subjects_affected="93" subjects_at_risk="323"/>
                <counts group_id="E2" events="110" subjects_affected="110" subjects_at_risk="336"/>
                <counts group_id="E3" events="102" subjects_affected="102" subjects_at_risk="329"/>
                <counts group_id="E4" events="45" subjects_affected="45" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="160" subjects_affected="160" subjects_at_risk="323"/>
                <counts group_id="E2" events="156" subjects_affected="156" subjects_at_risk="336"/>
                <counts group_id="E3" events="148" subjects_affected="148" subjects_at_risk="329"/>
                <counts group_id="E4" events="62" subjects_affected="62" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

